CIBC Asset Management Inc increased its stake in Chemed Co. (NYSE:CHE – Free Report) by 5.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 457 shares of the company’s stock after acquiring an additional 22 shares during the period. CIBC Asset Management Inc’s holdings in Chemed were worth $242,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. UMB Bank n.a. grew its stake in shares of Chemed by 300.0% during the fourth quarter. UMB Bank n.a. now owns 52 shares of the company’s stock valued at $28,000 after buying an additional 39 shares during the last quarter. Trust Co. of Vermont bought a new position in shares of Chemed during the fourth quarter valued at about $34,000. Allworth Financial LP grew its stake in shares of Chemed by 2,057.1% during the fourth quarter. Allworth Financial LP now owns 151 shares of the company’s stock valued at $83,000 after buying an additional 144 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Chemed by 2,314.3% during the third quarter. Farther Finance Advisors LLC now owns 338 shares of the company’s stock valued at $203,000 after buying an additional 324 shares during the last quarter. Finally, KBC Group NV grew its stake in shares of Chemed by 11.5% during the third quarter. KBC Group NV now owns 378 shares of the company’s stock valued at $227,000 after buying an additional 39 shares during the last quarter. 95.85% of the stock is currently owned by hedge funds and other institutional investors.
Chemed Price Performance
NYSE CHE opened at $551.28 on Wednesday. The stock has a market capitalization of $8.30 billion, a PE ratio of 27.86, a PEG ratio of 2.15 and a beta of 0.48. Chemed Co. has a 1 year low of $512.12 and a 1 year high of $654.62. The business’s 50-day moving average is $543.28 and its 200 day moving average is $563.22.
Chemed Announces Dividend
Insiders Place Their Bets
In related news, VP Brian C. Judkins acquired 145 shares of the stock in a transaction on Monday, December 30th. The stock was acquired at an average cost of $519.50 per share, for a total transaction of $75,327.50. Following the completion of the acquisition, the vice president now directly owns 1,678 shares of the company’s stock, valued at approximately $871,721. This represents a 9.46 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.32% of the stock is currently owned by company insiders.
Analyst Ratings Changes
CHE has been the topic of a number of recent research reports. Royal Bank of Canada reduced their price objective on Chemed from $697.00 to $633.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. StockNews.com raised Chemed from a “hold” rating to a “buy” rating in a research note on Saturday, November 30th.
Read Our Latest Analysis on CHE
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Read More
- Five stocks we like better than Chemed
- Insider Buying Explained: What Investors Need to Know
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Buy P&G Now, Before It Sets A New All-Time High
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- How to Calculate Stock Profit
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.